1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Lilly’s Tirzepatide Shows Benefit In Heart Failure, Including Outcomes

 
• By Jessica Merrill

Lilly is the first to demonstrate a benefit on heart failure outcomes with an incretin, even though rival Novo Nordisk already filed heart failure data for Wegovy with the US FDA. 

Lilly's tirzepatide showed a benefit in heart failure • Source: Shutterstock

Eli Lilly and Company reported positive heart failure data for tirzepatide, its blockbuster GIP/GLP-1 agonist, following rival Novo Nordisk A/S, which already showed a benefit in heart failure symptoms with semaglutide. Lilly, however, is the first company to show a benefit on heart failure outcomes with an incretin and tirzepatide also outperformed SGLT-2 inhibitors approved for heart failure on outcomes.

Key Takeaways
  • Lilly’s SUMMIT trial testing tirzepatide is the first incretin drug to show a benefit on heart failure outcomes.
  • Tirzepatide showed an impressive benefit on heart failure outcomes in patients with obesity that appear better than other drugs approved for HFpEF including SGLT-2 inhibitors

Lilly announced the positive topline results of the Phase III SUMMIT trial on 1 August

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 
• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.

CNS, Cardiometabolics A Bright Spot In Recent Chinese VC/PE Fundings

 
• By Dexter Jie Yan

Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.

Sebela’s Tegoprazan Poised For GERD Market

 
• By Jessica Merrill

Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).

MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors

 
• By Joseph Haas

The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.

More from Therapy Areas

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 
• By Jessica Merrill

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 
• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.